ONESOURCE Onesource Specialty Pharma Q4 FY26 results (Jan–Mar 2026) and concall
OneSource Specialty Pharma Limited reported a strong Q4 FY26, with revenue growing 47% sequentially to INR 4,282 million and EBITDA increasing over 5x, driven by Semaglutide launches and DDC invoicing. Full-year revenue saw a 2% decline due to prior quarter delays. The company is progressing with capacity expansion, with the second DDC line expected in Q2, and is reiterating its FY28 guidance of US$400 million revenue and 40% EBITDA margins. A proposed scheme to integrate related injectables businesses was deferred due to investor valuation concerns.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 0.5%, net profit down 94.9% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 393 | 426 | 327 | 376 | 290 −26% | 428 +0% |
| EBITDA | 142 | 183 | 88 | 106 | 17 −88% | 92 −50% |
| Net profit | -69 | 98 | 0 | 10 | -89 −29% | 5 −95% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
